Pulmonx (LUNG) Set to Announce Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is set to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Pulmonx to post earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. The company had revenue of $20.78 million during the quarter, compared to analysts’ expectations of $20.23 million. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Stock Down 1.8 %

Pulmonx stock opened at $6.13 on Wednesday. The firm has a market capitalization of $237.94 million, a price-to-earnings ratio of -3.98 and a beta of 0.64. The company’s 50 day simple moving average is $7.30 and its 200 day simple moving average is $7.35. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. Pulmonx has a fifty-two week low of $5.46 and a fifty-two week high of $14.84.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wells Fargo & Company lowered their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Canaccord Genuity Group boosted their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Insider Activity at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the transaction, the director now owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Steven S. Williamson bought 14,245 shares of the stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $6.84 per share, with a total value of $97,435.80. Following the acquisition, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the sale, the director now owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,351 shares of company stock valued at $361,494 over the last ninety days. 5.70% of the stock is owned by corporate insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.